Farallon Capital Management LLC Sells 2,912,800 Shares of IQVIA Holdings Inc. $IQV

Farallon Capital Management LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 75.6% in the 3rd quarter, Holdings Channel reports. The fund owned 938,551 shares of the medical research company’s stock after selling 2,912,800 shares during the quarter. Farallon Capital Management LLC’s holdings in IQVIA were worth $178,268,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in shares of IQVIA in the 3rd quarter worth approximately $14,278,000. Eagle Rock Investment Company LLC raised its stake in IQVIA by 33.6% during the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after buying an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new stake in IQVIA in the third quarter worth $4,008,000. Amundi grew its stake in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new position in shares of IQVIA during the third quarter valued at $7,368,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE IQV opened at $164.78 on Monday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The stock has a 50-day moving average of $201.58 and a 200 day moving average of $206.93. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $27.96 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.59 and a beta of 1.40.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup lowered their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Buy” and a consensus target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.